Our preliminary analysis has revealed key insights about CHILD HEALTH IMPRINTS (CHIL) PTE. LTD.'s performance and market presence. Here‘s a summary of our findings:
Has been operational for several years
Official business profile found on major search engines
32501
Manufacture of medical research and clinical diagnostic instruments and supplies (e.g. reagents)
Research and experimental development on medical science
Recently transacted with CHILD HEALTH IMPRINTS (CHIL) PTE. LTD.?
How would you rate your overall satisfaction?
Be a part of the community and help others make informed decisions by sharing your experience. Your feedback not only helps the business improve but also assists other customers in choosing the best services and products available.
This is only a preview of the TrustScore results for CHILD HEALTH IMPRINTS (CHIL) PTE. LTD., showcasing a few facets of its business that we have analysed.
Established Stage
A established brand is one that has achieved a strong, recognisable presence in its market or industry. These brands are well-known, trusted and often considered as key brands in their space. They have a significant loyal customer base, a clear and consistent identity, and a proven track record of success and growth.
CHILD HEALTH IMPRINTS (CHIL) PTE. LTD. has been operational for several years, indicating stability and reliability. Companies with a long history of operations are generally considered more trustworthy. The company's address in use by other companies, may raise concerns about the company's credibility and legitimacy.
CHILD HEALTH IMPRINTS (CHIL) PTE. LTD. has no presence on career platforms and provides no public information about its work environment or employee satisfaction. This lack of transparency may indicate less focus on employee well-being or difficulty in attracting talent, potentially impacting CHILD HEALTH IMPRINTS (CHIL) PTE. LTD.'s long-term success.
The company is not blacklisted by CaseTrust, which is a positive indicator of its credibility. The company is not on the MAS Enforcement List, which is a positive indicator of its compliance with financial regulations. The company is not accredited by CaseTrust. This lack of accreditation may raise concerns about the company's credibility and trustworthiness.
The company maintains an official business profile on major search engines, enhancing its visibility and credibility. CHILD HEALTH IMPRINTS (CHIL) PTE. LTD. may not have accessible contact information online, which dilutes engagement and credibility.
Sign in to view the analysis and detailed metrics for CHILD HEALTH IMPRINTS (CHIL) PTE. LTD.
Sign In to ContinueThey plan to expand their manufacturing base in South Korea. Child Health Imprints (CHIL), a Singapore-based neonatal-clinical care improvement firm, has raised $3.26m (US$2.3m) in Pre-Series A funding led by HealthXCapital, with participation from Enterprise SG and other HNIs. CHIL aims to improve clinical outcomes in Neonatal ICUs using IoT system and digitization. The company develops and applies informational and computational technologies including IoT, artificial intelligence (AI), and predictive analysis to improve the early diagnosis of critical diseases and overall quality of neonatal intensive care units across the world.
Singapore-based neonatal-clinical solutions startup Child Health Imprints (CHIL) has raised $2.4 million in its pre-Series A funding round led by healthcare investor HealthXCapital, according to an announcement. CHIL said the fresh capital raised in the funding round, which was also backed by Enterprise SG and high net worth individuals, will go towards expanding its integrated neonatal ICU (NICU) care services in Asia Pacific as well as in securing international regulatory approvals. The healthcare startup said it develops proprietary NICU solutions to provide real-time data and analytics to clinicians so they can easily monitor and treat newborn babies who are at risk.
CHILD Health Imprints (CHIL), a Singapore-based technology company focusing on neonatal clinical care, on Thursday announced it has raised US$2.3 million in pre-Series A funding. The round was led by Asian early-stage venture capital fund HealthXCapital which focuses on healthcare tech investments in South and South-east Asia. Other participants included Enterprise Singapore’s investment arm Seeds Capital, as well as high net worth individuals. CHIL aims to improve clinical outcomes in neonatal intensive care units (NICUs) by helping clinicians monitor and treat at-risk newborn babies. Its proprietary solutions aggregate in real-time the infants’ vital data, bedside clinical observations and laboratory results, and then analyse the data in medically comprehensive formats.
Have questions? We’re here to help you.
Scam.SG's TrustScore is an AI-driven engine that evaluates a business's trustworthiness by analysing data such as customer feedback, behavioral patterns, and compliance records. This comprehensive assessment results in a numerical score reflecting the entity's reliability.
ZIG MEDTECH ASIA PTE. LTD.
AGILENT TECHNOLOGIES SINGAPORE (INTERNATIONAL) PTE. LTD.
10X GENOMICS PTE. LTD.
DELECE PTE. LTD.
MAGNON PTE. LTD.